

LISTING OF THE CLAIMS

1. (cancelled)
2. (currently amended) A pharmaceutical composition for treating a hepatic disorder and/or for increasing the number of immune cells and platelets in a patient consisting essentially of a therapeutically effective amount of a buffered aqueous extract of Actaea rubra, Anemone hepatica ~~and~~, Anemone nemorosa, Nigella sativa, ~~and~~ Ranunculus arvensis, and a pharmaceutically acceptable carrier, wherein the extract of ~~Nigella sativa~~ is present in a concentration of not less than 20% weight per volume.
3. (cancelled)
4. (previously presented) A composition according to claim 2, wherein the composition is in a form of a tablet or capsule.
5. (previously presented) A composition according to claim 2, wherein the composition is in a form of a liquid or suspension.
6. (previously presented) A composition according to claim 2, wherein the composition is in a form of a sterile preparation for intra-muscular, subcutaneous, or intra-venous injection.

7. (previously presented) A composition according to claim 2, wherein the composition is in a form of nasal spray.

8. (previously presented) A composition according to claim 2, wherein the composition is in a form of a topical application.

9. (previously presented) A composition according to claim 2, wherein the composition is in a form of a transdermal system.

10. (previously presented) A composition according to claim 2, wherein the composition is in a form of suppository.

11.-26. (cancelled)

27. (previously presented) The pharmaceutical composition of claim 2, wherein the composition is effective for treating patients suffering from a hepatic disorder selected from the group consisting of chronic hepatitis, advanced/late stage hepatitis, hepatitis caused by hepatitis virus genotypes I, II, III or IV, a hepatic disorder characterized by fibrosis and/or cirrhosis, a hepatic disorder resulting from an autoimmune disease and a hepatic disorder resulting from a drug treatment.

28. (previously presented) The composition of claim 27, wherein the patients suffering from said hepatic disorder exhibit advanced stage liver disease characterized by fibrosis

and cirrhosis, and wherein treating with said composition results in modifying disease activity, including but not limited to, a decrease in hepatitis viral load, and a decrease in liver enzymes alanine aminotransferase (ALT) levels and aspartate aminotransferase (AST) levels.

29. (previously presented) The composition of claim 2, wherein said composition is effective in treating the cirrhosis and fibrosis associated with an advanced/late stage hepatic disorder.